a new dosage in 5 key points

• This new dosage of Eylea (8 mg/0.07 ml) is supported for the treatment, in adults:

– the neovascular (wet) form of subfoveal exudative age-related macular degeneration (AMD);

– reduction in visual acuity due to diabetic macular edema (DME), in the case of diffuse form or leaks close to the center of the macula, in patients as soon as visual acuity drops to 7/10 Parinaud 3 or less and in whom diabetes management has been optimized.

• A recombinant fusion protein, aflibercept binds to vascular endothelial growth factor-A (VEGF-A) and prevents its activation.
• Eylea 114.3 mg/ml makes it possible to offer patients injection intervals of up to 4 months as maintenance treatment (or even 5 months in certain stabilized patients), with efficacy and safety comparable to those of treatment with standard dose of 2 mg.
• The bottle should be stored in the refrigerator between +2°C and +8°C in its outer packaging.
• The prescription of this exceptional medication listed on List I (box of 1 vial + 1 filter needle, CIP: 34009 302 833 2 5) is reserved for ophthalmology specialists. Its price, excluding dispensing fees, is set at €766.85 versus €640.71 for Eylea 40… It remains 100% reimbursed.